"The voice for cancer physicians and their patients in Massachusetts."
Oncopeptides announces J-code J9247 for Pepaxto® (melphalan flufenamide) injection, 1mg. This J-code will be effective on October 1, 2021.
Effective July 1, 2020, ENHERTU J-Code is available. Identify ENHERTU with J9358.
The Centers for Medicare & Medicaid Services (CMS) released the July 2020 Quarterly Healthcare Common Procedural Coding System (HCPCS) File, which includes the designation of J9177 for PADCEV with the effective date of July 1, 2020.
For dates of service on or after July 1, 2020, the Centers for Medicare and Medicaid Services (CMS) has issued a product-specific J-code: J0791 for injection, crizanlizumab-tmca (Adakveo), 5 mg. The updated billing unit is 5 mg.
The Centers for Medicare and Medicaid Services (CMS) has assigned a permanent J-code for Polivy (polatuzumab vedotin-piiq; Genentech). Effective January 1, 2020, the J-code is J9309 (Injection, polatuzumab vedotin-piiq, 1 mg).
Massachusetts Society of Clinical Oncologists (c)
